TY - JOUR
T1 - Characterization of childhood precursor T-lymphoblastic lymphoma by lmmunophenotyping and fluorescent in situ hybridization
T2 - A report from the Children's Oncology Group
AU - Smock, Kristi J.
AU - Nelson, Marilu
AU - Tripp, Sheryl R.
AU - Sanger, Warren G.
AU - Abromowitch, Minnie
AU - Cairo, Mitchell S.
AU - Perkins, Sherrie L.
PY - 2008/10
Y1 - 2008/10
N2 - Background. T-lymphoblastic lymphoma (T-LBL) accounts for 25-30% of childhood non-Hodgkin's lymphoma and is closely related to T-lymphoblastic leukemia (T-ALL). Recently, we demonstrated distinct differences in gene expression between childhood T-LBL and T-ALL, but molecular pathogenesis and relevant protein expression patterns in T-LBL remain poorly understood. Procedure. Children with T-LBL with disseminated disease were registered and treated on COG protocol 5971. Paraffin-embedded tumor tissue was obtained at diagnosis for immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) studies. We determined the pattern and intensity of staining for c-Myc, Skp2, Mib-1, p53, TCL-1, bcl-2, and bcl-6 proteins by IHC and c-Myc, p53, bcl-2, bcl-6, and TCR α/δ molecular alterations by FISH in 22 pediatric T-LBL cases. Results. The majority of T-LBL samples expressed Mib-1 (59%) and c-Myc (77%) proteins in greater than 50% of the cells, but Skp2 (14%), p53 (14%), and bcl-2 (23%) expression was less common. FISH studies demonstrated 18% gains and 10% losses in c-Myc, 16% gains in p53, 12% gains and 6% losses in bcl-2, and 6% gains and 19% losses in bcl-6 with little direct correlation between the IHC and FISH studies. Conclusions. Childhood T-LBL is a highly proliferative tumor associated with enhanced expression of c-Myc protein, but without detectable c-Myc molecular alterations. FISH studies did not identify consistent etiologies of molecular dysregulation, and future studies with other molecular approaches may be required to elucidate the molecular pathogenesis of childhood T-LBL.
AB - Background. T-lymphoblastic lymphoma (T-LBL) accounts for 25-30% of childhood non-Hodgkin's lymphoma and is closely related to T-lymphoblastic leukemia (T-ALL). Recently, we demonstrated distinct differences in gene expression between childhood T-LBL and T-ALL, but molecular pathogenesis and relevant protein expression patterns in T-LBL remain poorly understood. Procedure. Children with T-LBL with disseminated disease were registered and treated on COG protocol 5971. Paraffin-embedded tumor tissue was obtained at diagnosis for immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) studies. We determined the pattern and intensity of staining for c-Myc, Skp2, Mib-1, p53, TCL-1, bcl-2, and bcl-6 proteins by IHC and c-Myc, p53, bcl-2, bcl-6, and TCR α/δ molecular alterations by FISH in 22 pediatric T-LBL cases. Results. The majority of T-LBL samples expressed Mib-1 (59%) and c-Myc (77%) proteins in greater than 50% of the cells, but Skp2 (14%), p53 (14%), and bcl-2 (23%) expression was less common. FISH studies demonstrated 18% gains and 10% losses in c-Myc, 16% gains in p53, 12% gains and 6% losses in bcl-2, and 6% gains and 19% losses in bcl-6 with little direct correlation between the IHC and FISH studies. Conclusions. Childhood T-LBL is a highly proliferative tumor associated with enhanced expression of c-Myc protein, but without detectable c-Myc molecular alterations. FISH studies did not identify consistent etiologies of molecular dysregulation, and future studies with other molecular approaches may be required to elucidate the molecular pathogenesis of childhood T-LBL.
KW - Fluorescence in situ hybridization
KW - Immunohistochemistry
KW - Immunophenotyping
KW - Molecular analysis
KW - T-cell lymphoblastic lymphoma
UR - http://www.scopus.com/inward/record.url?scp=50249170951&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50249170951&partnerID=8YFLogxK
U2 - 10.1002/pbc.21666
DO - 10.1002/pbc.21666
M3 - Article
C2 - 18618503
AN - SCOPUS:50249170951
SN - 1545-5009
VL - 51
SP - 489
EP - 494
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 4
ER -